Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17022731 | 0.91 | CYP1A2 (0.45) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| SCHEMBL5180611 | 0.91 | CYP2C19 (0.38) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| SCHEMBL4090083 | 0.89 | CYP2C19 (0.39) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| SCHEMBL3972281 | 0.88 | CYP2C19 (0.43) | CYP1A2CYP2C9PAOXMEN1KMT2A | |
| SCHEMBL10245131 | 0.87 | PAOX (0.41) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| SCHEMBL19432370 | 0.86 | CYP2C9 (0.45) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| SCHEMBL9079152 | 0.85 | CYP2C19 (0.41) | CYP1A2CYP2C9PAOXMEN1KMT2A | |
| SCHEMBL4192702 | 0.83 | CYP2C19 (0.39) | CYP1A2MAPK1PAOXMEN1KMT2A | |
| Diethylaminoethanol SCHEMBL18769935 | 0.83 | CYP1A2 (0.45) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| Diethylaminoethanol SCHEMBL28133290 | 0.83 | CYP1A2 (0.45) | CYP1A2CYP2C9HPGDMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933223-B2 | Process for preparing a cyclic tertiary amine | BASF SE (DE) | 2015-01-13 | — | — | US | disclosed |
| EP-2627644-B1 | METHOD FOR PRODUCING A CYCLIC TERTIARY AMINE | BASF SE (DE) | 2014-12-10 | — | — | EP | disclosed |
| CN-103492404-A | C-4' substituted macrolide derivatives | TAISHO PHARMACEUTICAL CO LTD | 2014-01-01 | — | — | CN | disclosed |
| EP-2627644-A1 | METHOD FOR PRODUCING A CYCLIC TERTIARY AMINE | BASF SE (DE) | 2013-08-21 | — | — | EP | disclosed |
| CN-102908624-A | Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist | ASTRAZENECA SWEDEN AB | 2013-02-06 | — | — | CN | disclosed |
| CN-102088976-B | Comprising a muscarinic receptor antagonist and beta2-pharmaceutical products of adrenoreceptor agonists | ASTRAZENECA AB | 2012-12-26 | — | — | CN | disclosed |
| CN-101678005-B | Combination of a muscarinic receptor antagonist and a beta-2 adrenergic receptor agonist | ARGENTA DISCOVERY LTD | 2012-10-31 | — | — | CN | disclosed |
| CN-101282950-B | Novel benzothiazolone derivatives | ASTRAZENECA AB | 2012-09-12 | — | — | CN | disclosed |
| US-20120095221-A1 | PROCESS FOR PREPARING A CYCLIC TERTIARY AMINE | BASF SE (DE) | 2012-04-19 | — | — | US | disclosed |
| WO-2012049101-A1 | METHOD FOR PRODUCING A CYCLIC TERTIARY AMINE | BASF SE (DE) | 2012-04-19 | — | — | WO | disclosed |
| CN-102088976-A | Comprising a muscarinic receptor antagonist and beta2-pharmaceutical products of adrenoreceptor agonists | ASTRAZENECA AB | 2011-06-08 | — | — | CN | disclosed |
| CN-101748117-A | Sample dissociation and coating of reaction surface | QIAGEN GMBH | 2010-06-23 | — | — | CN | disclosed |
| CN-101678005-A | Combination of a muscarinic receptor antagonist and a beta-2 adrenergic receptor agonist | ARGENTA DISCOVERY LTD | 2010-03-24 | — | — | CN | disclosed |
| CN-101652137-A | Combinations of beta- 2 -adrenoceptor agonistic benzothiazolone | ASTRAZENECA AB SE | 2010-02-17 | — | — | CN | disclosed |
| CN-101605770-A | Salt 668 | ASTRAZENECA AB (SE) | 2009-12-16 | — | — | CN | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| CN-101300240-A | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3h)-one-derivatives as beta 2 adrenoceptor agonists | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | CN | disclosed |
| CN-101282950-A | Novel benzothiazolone derivatives | ASTRAZENECA AB (SE) | 2008-10-08 | — | — | CN | disclosed |
| CN-101133093-A | Sample lysis and coating of reaction surfaces | QIAGEN GMBH (DE) | 2008-02-27 | — | — | CN | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095221-A1 | PROCESS FOR PREPARING A CYCLIC TERTIARY AMINE | ADH1A, ADH1C, AOC2 | CYP1A2 17/4885CYP2C9 410/4885HPGD 589/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | CYP1A2 1928/4885CYP2C9 395/4885HPGD 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.